Filana Therapeutics (FLNA) Status Update summary

Study results and implications

• Phase III RETHINK ALZ study failed to meet co-primary, secondary, and exploratory biomarker endpoints for simufilam in mild to moderate Alzheimer's disease.

• Loss of cognition in the placebo group was less pronounced than in previous studies, prompting further analysis.

• Decision made to discontinue the second phase III trial, REFOCUS ALZ, and the open-label extension study.

• Detailed analyses of both studies will be reported in the future, with a complete 52-week dataset and much of the 76-week data available.

Study design and participant characteristics

• Study included a screening period and a treatment period, enrolling patients with mild to moderate dementia due to Alzheimer's.

• Participants were randomized 1:1 to simufilam or placebo; 60-62% had mild dementia, the rest moderate.

• Mean participant age was about 74 years, with 55% women.

Efficacy and safety outcomes

• Simufilam group showed a 0.39-point reduction in ADAS-Cog12 and a 0.51-point increase in ADCS-ADL, but neither reached statistical significance.

• No statistical significance found in mild or moderate subgroups for primary endpoints at week 52.

• Adverse events were balanced between groups, with dizziness more common in the simufilam group; overall safety profile considered favorable.